The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma. New Jersey-based Slayback is focused on generic and specialty pharmaceutical products.
Source: Press Release
Everstone Group to invest up to $50 mln in Slayback Pharma
The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: